Astex Therapeutics Overview
- Year Founded
-
1999
- Status
-
Acquired/Merged
- Employees
-
183
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$151M
Astex Therapeutics General Information
Description
Operator of a biotechnology company focused on the discovery and development of drugs in oncology and other areas. The company uses its fragment-based drug discovery technology to identify and develop new medicines, primarily for the treatment of cancer and antiviral diseases, thereby helping in optimizing the pharmacokinetic properties and safety of their lead compounds.
Contact Information
Website
www.astex-therapeutics.comCorporate Office
- 436 Cambridge Science Park
- Milton Road
- Cambridge CB4 0QA
- England, United Kingdom
Corporate Office
- 436 Cambridge Science Park
- Milton Road
- Cambridge CB4 0QA
- England, United Kingdom
Astex Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 20-Jul-2011 | $151M | Completed | Profitable | ||
| 7. Later Stage VC | 21-Dec-2010 | Completed | Profitable | |||
| 6. Grant | 02-Mar-2009 | Completed | Profitable | |||
| 5. Later Stage VC | Completed | Profitable | ||||
| 4. Later Stage VC | 05-Nov-2003 | Completed | Profitable | |||
| 3. Early Stage VC | 17-Dec-2001 | Completed | Product Development | |||
| 2. Early Stage VC | 14-May-2001 | $32.5M | $32.5M | Completed | Product Development | |
| 1. Early Stage VC | 03-Dec-1999 | Completed | Product Development |
Astex Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| C Preferred Ordinary | ||||||||
| B Preferred Ordinary |
Astex Therapeutics Patents
Astex Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4436571-A1 | Small molecule inhibitors of kras mutated proteins | Pending | 24-Nov-2021 | ||
| EP-4436571-A4 | Small molecule inhibitors of kras mutated proteins | Pending | 24-Nov-2021 | ||
| US-20260200925-A1 | Small molecule inhibitors of kras mutated proteins | Pending | 24-Nov-2021 | ||
| WO-2023097227-A1 | Small molecule inhibitors of kras mutated proteins | Inactive | 24-Nov-2021 | ||
| JP-2024543879-A | Small molecule inhibitors of mutant kras proteins | Pending | 24-Nov-2021 | A61K45/06 |
Astex Therapeutics Signals
Astex Therapeutics Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Abingworth | Venture Capital | Minority | ||
| Advent International | PE/Buyout | Minority | ||
| Alta Partners | Venture Capital | Minority | ||
| Gimv | PE/Buyout | Minority | ||
| Novartis Venture Fund | Corporate Venture Capital | Minority |
Astex Therapeutics FAQs
-
When was Astex Therapeutics founded?
Astex Therapeutics was founded in 1999.
-
Where is Astex Therapeutics headquartered?
Astex Therapeutics is headquartered in Cambridge, United Kingdom.
-
What is the size of Astex Therapeutics?
Astex Therapeutics has 183 total employees.
-
What industry is Astex Therapeutics in?
Astex Therapeutics’s primary industry is Drug Discovery.
-
Is Astex Therapeutics a private or public company?
Astex Therapeutics is a Private company.
-
What is the current valuation of Astex Therapeutics?
The current valuation of Astex Therapeutics is .
-
What is Astex Therapeutics’s current revenue?
The current revenue for Astex Therapeutics is .
-
How much funding has Astex Therapeutics raised over time?
Astex Therapeutics has raised $87.8M.
-
Who are Astex Therapeutics’s investors?
Abingworth, Advent International, Alta Partners, Gimv, and Novartis Venture Fund are 5 of 8 investors who have invested in Astex Therapeutics.
-
When was Astex Therapeutics acquired?
Astex Therapeutics was acquired on 20-Jul-2011.
-
Who acquired Astex Therapeutics?
Astex Therapeutics was acquired by Astex Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process